Showing results (431-440 of 1,877) with videos related to

Sort By:
Pageof 188
Immunotherapy|May 7, 2025
Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 updateIlias Giannakodimos, Afroditi Ziogou, Alexios Giannakodimos, et al.
Immunotherapy|April 25, 2025
Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospectsAlexandria Matic, Vera Bril
Immunotherapy|March 14, 2025
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative reviewAfroditi Ziogou, Alexios Giannakodimos, Ilias Giannakodimos, et al.
Immunotherapy|March 8, 2025
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and managementCarolina Colli Cruz, Maria Julia Moura Nascimento Santos, Sharada Wali, et al.
Immunotherapy|February 27, 2025
ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Eric Simpson, Robert Bissonnette, et al.
Immunotherapy|June 28, 2024
Adjuvant ArtinM favored the host immunity against Cryptococcus gattii infection in C57BL/6 micePatrícia Kellen Martins Oliveira-Brito, Gabriela Yamazaki de Campos, Júlia Garcia Guimarães, et al.
Immunotherapy|June 18, 2024
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization studyPauline M Ellerbroek, Leif G Hanitsch, Torsten Witte, et al.
Immunotherapy|June 18, 2024
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series studyLiu Jia, Shi Yuequan, Fang Jian, et al.
Immunotherapy|December 17, 2025
Multisystem immune-related adverse events during combined ipilimumab-nivolumab with subsequent disease progression: a case reportElsa Jonsdottir, Ivan Arni Robertsson, Agust Hilmarsson, et al.
Immunotherapy|January 10, 2024
Patterns of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitorsJohn C Hunting, Andrew T Faucheux, Sarah N Price, et al.
Pageof 188